Suchergebnisse - "Antineoplastic Agents, Immunological"

PubPharm (10.646)

1

Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia

enthalten in: Leukemia & lymphoma | 2024

von Tadmor, T. | Levy Yurkovski, I.

2

Complications of immuno-oncology care : what urologist should know

enthalten in: BJU international | 2024

von Grajales, V. | Martini, A. | Shore, N.

3

Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer : recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines

enthalten in: Breast cancer (Tokyo, Japan) | 2024

von Hattori, M. | Honma, N. | Nagai, S. | +18

4

Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

enthalten in: Lung | 2024

von Ramoni, D. | Coco, S. | Rossi, G. | +14

5

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

enthalten in: Clinical and translational medicine | 2024

von Massa, C. | Karn, T. | Weber, K. | +19

6

Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer

enthalten in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2024

von Smesseim, I. | Mets, O. | Daniels, J. | +2

7

Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound

enthalten in: BMJ case reports | 2024

von Harnden, K. | Di Matteo, A. | Howell, K. | +1

8

Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)

enthalten in: Zhonghua zhong liu za zhi [Chinese journal of oncology | 2024

von Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group

9

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma : Real-world evidence from Sweden

enthalten in: Cancer medicine | 2024

von Uttervall, K. | Tätting, L. | Lemonakis, K. | +6

10

Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events

enthalten in: Clinical genitourinary cancer | 2024

von Nizam, A. | Rader, R. | Tzeng, A. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[1065]